Drug data · shortage, price, volume

Is your drug short, and what do pharmacies pay for it?

Each page below puts three public records on one timeline: the FDA drug shortage list, CMS's weekly pharmacy acquisition cost (NADAC) and Medicaid prescriptions filled. Every figure is rebuilt from dated federal snapshots, and every gap in the data is shown instead of smoothed over.

9drugs with a pageeach has FDA listing history, a price series and a shortage clock

20months, the median shortageacross 430 FDA listings since 2014

9listed as short todayon the FDA list as of 2026-10-27

Find a drug

Pills and liquids on the FDA shortage list

These are the dosage forms people fill at a retail pharmacy. The red strip is the months the FDA listed the form as short; the blue line is the pharmacy benchmark price.

Rifampin capsule On the FDA list 58 months $0.672 per capsule now, -3% since 2021 Mixed amphetamine salts (Adderall)C-II tablet On the FDA list 48 months $0.286 per tablet now, -20% since 2021 Clonazepam (Klonopin)C-IV tablet On the FDA list 43 months $0.025 per tablet now, -22% since 2021 Lisdexamfetamine (Vyvanse)C-II capsule On the FDA list 39 months $12.35 per capsule now, +15% since 2021 Methylphenidate (Concerta)C-II ER tablet On the FDA list 39 months $0.719 per tablet now, -34% since 2021

Injectables on the FDA shortage list

Mostly bought by hospitals and clinics. NADAC prices only what retail pharmacies buy, so these price lines are thinner; we show a drug here only when its price series runs unbroken for at least three years up to today.

Ketorolac injectable On the FDA list 103 months $1.00 per mL now, -31% since 2021 Furosemide injectable On the FDA list 78 months $0.529 per mL now, +54% since 2023 Methotrexate injectable On the FDA list 43 months $1.75 per mL now, -27% since 2021 Heparin injectable On the FDA list 37 months $1.22 per mL now, -40% since 2021

How these pages are built

A drug gets a page when one dosage form has been on the FDA list for at least a year, has at least eight priced products, and has an unbroken price series of three years or more. 64 other drugs with FDA history or prices are not shown yet because their price data has holes or their forms do not line up; we would rather show fewer pages than draw a line across a gap.

Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote and not what any patient paid. The FDA list should not be relied on for medical care; ask a pharmacist about supply.

Sources. FDA Drug Shortages (snapshot 2026-10-27), CMS NADAC and State Drug Utilization Data on data.medicaid.gov, the openFDA NDC directory, and Internet Archive captures of the FDA list for monthly history. Figures are OmniRx calculations, not statements by CMS or FDA.